Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Shire PLC ($SHPG) announced that the European Medicines Agency has approved expanded indications for its hereditary angioedema treatment CINRYZE (C1 inhibitor [human]). The product may now be used for routine prevention of angioedema attacks in children as young as six years with severe and recurrent attacks of HAE who are intolerant of or inadequately protected by oral preventative treatments or who are inadequately managed with repeated acute treatment. The treatment was first approved in the EU in June 2011. 
Shire stock has gained 10 percent in the past 12 months. Its Year to Date gain stands at a little over 4 percent.

Trovagene ($TROV) announced signing a new deal with Nerviano Medical Sciences. The deal pertains to exclusive global development and commercialization rights to NMS-1286937, renamed PCM-075, for the potential treatment of acute myeloid leukemia. The terms of the deal entail that Trovagene will pay an upfront fee of $2 million, milestone payments and sales-based royalties. The parties did not disclose additional financial terms and conditions.
The stock price reacted negatively to the news, plummeting more than 20 percent in its pre-market session, turning its Year to Date performance to negative. The company stock has lost more than 67 percent of its value in the past 12 months.

 

Heat Biologics ($HTBX) announced receiving a delisting notice from Nasdaq for failing to comply with its minimum bid price of $1. The company has 180 days to address the issue which can be done with a reverse split of its common shares, if necessary.

Pfizer ($PFE) reported that its  XELJANZ has been approved by the Chinese Food and Drug Administration for the treatment of adults with moderate-to-severely active rheumatoid arthritis who have had an inadequate response or are intolerant of methotrexate. The drug may be  used in combination with MTX or other biologic disease-modifying antirheumatic drugs. It was approved in the U.S. in 2012 and is currently available in over 50 countries.

Cesca Therapeutics ($KOOL) reported its results from a 24-subject study in India assessing the safety and efficacy of autologous platelet rich plasma (PRP) using point-of-care platform for treating chronic non-healing ulcers showed a treatment benefit.  All 24 participants experienced healing, with almost 71% (n=17/24) showing a 90% reduction in wound size. No adverse events were observed on the treatment day or during the 24 weeks of follow-up.

Endo International ($ENDP) reported that the joint meeting the FDA's Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee over its New Drug Application seeking abuse-deterrent labeling for opioid medication OPANA ER has voted against the company.

 

Corindus Vascular Robotics ($CVRS) reported that it has inked a new deal with WakeMed Health & Hospitals. The collaboration pertains to developing a national center of excellence to advance patient care and clinical robotics research, including training interventional cardiologists on robotic-assisted percutaneous coronary interventions using the CorPath GRX System.

PTC Therapeutics ($PTCT) announced inking a deal with privately eld Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza (deflazacort). The treatment was approved last month by the FDA to treat Duchenne muscular dystrophy. Under the terms of the deal, PTC will pay Marathon $140 million upfront. $75 million of this will be paid in cash while $65 million will be paid in PTC common stock. The annual sales-based payments beginning in 2018. Marathon will also have the opportunity to receive a single $50 million sales-based milestone.

 

Hikma Pharmaceuticals ($HKMPF) reported better than expected results for its financial year. The company’s core operating profit rose to $419 million for the year ended Dec. 31 from $409 million. The market expectations were pegged at $375 million. Hikma also reported that its new launches including Advair, are expected to contribute about 15 percent of the generics revenue in 2017.

Novelion Therapeutics Inc. ($NVLN) reported that its GAAP net product sales stood at $13.6 million in the fourth quarter and for the full year of 2016.  Full-year pro forma total net product sales were $153.2 million. For the full year of 2017, Novelion expects its total net products sales in the range of $155 million and $165 million.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Jefferies Group LLC
Reiterates
Aclaris Therapeutics (ACRS)
Buy
$36.00
Low
Maxim Group
Raises Target
AEterna Zentaris (AEZS)

$11.00
Low
Royal Bank of Canada
Reiterates
Almost Family (AFAM)
Outperform -> Outperform
$55.00 -> $56.00
Low
Leerink Swann
Downgrades
Biogen (BIIB)
Outperform -> Market Perform

Medium
Morgan Stanley
Downgrades
Biogen (BIIB)
Overweight -> Equal Weight
$305.00
Low
Credit Suisse Group AG
Initiates
Bioverativ (BIVV)
Underperform
$45.00
High
Credit Suisse Group AG
Reiterates
Coherus Biosciences (CHRS)
Buy

Low
Aegis
Reiterates
Conatus Pharmaceuticals (CNAT)
Buy
$11.00
Low
Stifel Nicolaus
Raises Target
Conatus Pharmaceuticals (CNAT)
Buy -> Buy
$7.00 -> $9.00
Low
Jefferies Group LLC
Reiterates
Charles River Laboratories Intl. (CRL)
Buy

Low
Jefferies Group LLC
Reiterates
DBV Technologies SA - (DBVT)
Buy

Low
Societe Generale
Upgrades
DBV Technologies SA - (DBVT)
Hold -> Buy

Low

Gainers (% price change)Last TradeChangeMkt CapOclaro, Inc.OCLR8.73+0.63 (7.78%)1.40BClovis Oncology IncCLVS71.93+4.98 (7.44%)3.21BAntares Pharma IncATRS2.75+0.16 (6.18%)443.62MKeryx BiopharmaceuticalsKERX5.71+0.30 (5.55%)598.20MLeMaitre Vascular IncLMAT24.08+1.22 (5.34%)460.26MLosers (% price change)Vermillion, Inc.VRML2.20-0.15 (-6.38%)111.66MBioDelivery Sciences IntlBDSI2.00-0.08 (-3.61%)112.29MImmunoGen, Inc.IMGN3.76-0.12 (-3.09%)328.45MInsys Therapeutics IncINSY10.55-0.27 (-2.50%)757.18MAlliance HealthCareAIQ9.85-0.25 (-2.48%)105.98MMost Actives (dollar volume)Johnson & JohnsonJNJ128.96+1.91 (1.50%)350.94BAmgen, Inc.AMGN182.60+2.48 (1.38%)133.79BPfizer Inc.PFE34.63+0.42 (1.21%)206.78BCelgene CorporationCELG126.88+2.20 (1.76%)98.91BBristol-Myers Squibb CoBMY57.65+0.96 (1.69%)96.03B